Predicted vs observed CVD events
| Variable . | N . | CVD events expected . | CVD events observed . | RR (95% CI) . | Fischer exact test, P . | Absolute risk reduction . |
|---|---|---|---|---|---|---|
| Total | 579 | 4.1% (24) | 1.7% (9) | 0.38 (0.18-0.80) | .01 | 2.4% |
| CVD risk group | ||||||
| Low | 401 | 1.5% (6) | 0.2% (1) | 0.17 (0.02-1.38) | .12 | 1.3% |
| Intermediate | 100 | 7.0% (7) | 3.0% (3) | 0.43 (0.11-1.61) | .17 | 4.0% |
| High | 78 | 15.3% (12) | 6.4% (5) | 0.42 (0.15-1.13) | .06 | 8.9% |
| Severity | ||||||
| Mild | 201 | 5.0% (10) | 1.0% (2) | 0.20 (0.04-0.90) | .02 | 4.0% |
| Nonsevere* | 275 | 4.7% (13) | 1.8% (5) | 0.38 (0.14-1.06) | .045 | 2.9% |
| Severe | 304 | 3.9% (12) | 1.3% (4) | 0.33 (0.11-1.02) | .04 | 2.6% |
| On-prophylaxis therapy | 182 | 3.8% (7) | 2.2% (4) | 0.57 (0.17-1.92) | .27 | 1.7% |
| On-demand therapy | 122 | 4.1% (5) | 0% (0) | 0.00 | .03 | 4.1% |
| Variable . | N . | CVD events expected . | CVD events observed . | RR (95% CI) . | Fischer exact test, P . | Absolute risk reduction . |
|---|---|---|---|---|---|---|
| Total | 579 | 4.1% (24) | 1.7% (9) | 0.38 (0.18-0.80) | .01 | 2.4% |
| CVD risk group | ||||||
| Low | 401 | 1.5% (6) | 0.2% (1) | 0.17 (0.02-1.38) | .12 | 1.3% |
| Intermediate | 100 | 7.0% (7) | 3.0% (3) | 0.43 (0.11-1.61) | .17 | 4.0% |
| High | 78 | 15.3% (12) | 6.4% (5) | 0.42 (0.15-1.13) | .06 | 8.9% |
| Severity | ||||||
| Mild | 201 | 5.0% (10) | 1.0% (2) | 0.20 (0.04-0.90) | .02 | 4.0% |
| Nonsevere* | 275 | 4.7% (13) | 1.8% (5) | 0.38 (0.14-1.06) | .045 | 2.9% |
| Severe | 304 | 3.9% (12) | 1.3% (4) | 0.33 (0.11-1.02) | .04 | 2.6% |
| On-prophylaxis therapy | 182 | 3.8% (7) | 2.2% (4) | 0.57 (0.17-1.92) | .27 | 1.7% |
| On-demand therapy | 122 | 4.1% (5) | 0% (0) | 0.00 | .03 | 4.1% |
Fisher exact test with a two-sided P value. CVD risk groups are divided by their 10 years’ risk (<10%; 10%-20%; and >20% risk); the expected risk for 5 years’ follow-up is therefore lower.
Combination of mild and moderate to severe disease.